Q&A: Cee-ing the benefits

Article

After the recent launch of CROMA's EYE-Cee One hydrophobic one-piece aspheric intraocular lens (IOL) with blue light filter, we spoke with Dr Jean-Michel Bosc on his experiences and opinions of this new product...

After the recent launch of CROMA's EYE-Cee One hydrophobic one-piece aspheric intraocular lens (IOL) with blue light filter, we spoke with Dr Jean-Michel Bosc on his experiences and opinions of this new product. Dr Bosc is an ophthalmic surgeon based in the Clinique Sourdille in Nantes, France. He specializes in cataract surgery and has already implanted 120 EYE-Cee One IOLs.

Could you please describe the main features of the new CROMA lens?The EYE-Cee One is a one-piece hydrophobic aspheric IOL with a blue light filter. It features a dense polymer network to reduce glistening or whitening of the material, anchor-wing haptics design so that fixation within the capsular bag is stabilized, the 360° sharp edges prevent cells from using the haptic-optic junction and improves capsular fusion. Additionally, the lens has a sand-blasted-like surface of the haptics, which reduces haptic stickiness on the optic, improves haptic visibility and the handling with the injector during implantation.

In your opinion what are the main advantages gained with this new lens?In my opinion the material used in this lens is extremely stable, there are no microvacuoles at all. I have found that the lens centres immediately and correctly without any rotation after implantation and the 90º haptic-optic position optimally balances the capsular bag contractions. Also, because of the anchor-wing haptics design the stability of fixation within the capsular bag is maintained over time meaning that this could be ideal for a toric lens. In my experience with this lens I have also found it to be extremely easy to implant. EYE-Cee One has a negative aspheric optic design and the sand-blasted-like surface of the lens edges reduces edge glare and stray light usually caused by ordinary lens edge reflection. These features of the IOL together with the integrated blue light filter have given my patients perfect vision and optimal refractive outcome after surgery.

What postoperative results have you found most pleasing?Up-to-now I have not experienced any cases of posterior capsule opacification (PCO) or any fibrosis during post-op follow-up with my patients, which can be a common side effect after lens implantation. Furthermore, when I have requested information from my patients regarding their level of satisfaction they have stated that they are very happy with their visual quality after the operation and also they have not complained about glare.

Is there anything else you would like to add?I have been completely satisfied with this lens not only in the ease of use but also the way in which it behaves once implanted and the refractive outcomes it affords my patients. Therefore, I am more than happy to recommend the EYE-Cee One to my colleagues.

If you would like more information regarding this IOL please contactCROMA-Pharma GmbHStockerauerstrasse 1812100 KorneuburgAustriaOr visit the website: www.croma.at

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.